Gilead Science公司打破了对收入的预期,提高了股票前景,并维持了2025年的指导。 Gilead Sciences beat earnings expectations, raised stock outlook, and maintained 2025 guidance.

Gilead Science公司报告第二季度收入丰厚,其收入为2.01 EPS和70.8亿美元,超过预期,并保持了2025年全年指导。 Gilead Sciences reported strong second-quarter earnings, with $2.01 EPS and $7.08 billion in revenue, exceeding expectations, and maintained its 2025 full-year guidance. 该公司的股票在本季度上涨了3.4%,交易额接近116.78美元,市场上限为144.9亿美元。 The company’s stock rose 3.4% in the quarter, trading near $116.78 with a market cap of $144.9 billion. 包括特鲁斯特公司和JP摩根公司在内的多家公司更新了股票,以业绩优异和“最佳购买”共识评级为117.17美元的目标,将股票升级。 Multiple firms, including Truist and JPMorgan, upgraded the stock, citing strong performance and a "Moderate Buy" consensus rating with a $117.17 target. 内幕人士在90天内出售了82 000股,而Friedenthal Finance和Valeo Financial Advisors等机构则增加了股份。 Insiders sold 82,000 shares in 90 days, while institutions like Friedenthal Financial and Valeo Financial Advisors increased stakes. Gilead宣布季度红利为0.79美元,收益为2.7%。 Gilead declared a quarterly dividend of $0.79, yielding 2.7%.